EMILY MOORE: Open Payments
NPI 1730436668 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,259 in 148 payments from 16 companies in 2025. Trend: 2023 $1,834 · 2024 $1,983 · 2025 $2,259
Food & beverage: $2,259
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $337 |
| ABBVIE INC. | 24 | $245 |
| Alkermes, Inc. | 14 | $234 |
| Corium, LLC | 14 | $220 |
| E.R. Squibb & Sons, L.L.C. | 17 | $203 |
| Neurocrine BioSciences, Inc. | 15 | $196 |
| Vanda Pharmaceuticals Inc. | 12 | $179 |
| Axsome Therapeutics, Inc. | 8 | $149 |
| Janssen Pharmaceuticals, Inc | 8 | $144 |
| Supernus Pharmaceuticals, Inc. | 9 | $138 |
Products named: CAPLYTA, VRAYLAR, ARISTADA, Azstarys, INGREZZA, COBENFY, FANAPT, Auvelity.
Industry payments across OK — which companies pay providers there.
